ETF DAILY NEWS

Atyr PHARMA (NASDAQ:ATYR) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR – Free Report) in a research note published on Friday morning,Benzinga reports. They currently have a $35.00 price objective on the stock. A number of other research firms have also issued reports on ATYR. Leerink Partners began coverage on Atyr PHARMA in a […]

Mar 17, 2025 - 07:15
 0
Atyr PHARMA (NASDAQ:ATYR) Earns “Buy” Rating from HC Wainwright
HC Wainwright reissued their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR – Free Report) in a research note published on Friday morning,Benzinga reports. They currently have a $35.00 price objective on the stock. A number of other research firms have also issued reports on ATYR. Leerink Partners began coverage on Atyr PHARMA in a […]
Read More

Tags:

Previous Article

Lyra Therapeutics (NASDAQ:LYRA) Given Neutral Rating at HC Wainwright

Next Article

ARMOUR Residential REIT (NYSE:ARR) and Empire State Realty Trust (NYSE:ESRT) Fin...

Related Posts

Steward Partners Investment Advisory LLC Raises Holdings in Schwab International Equity ETF (NYSEARCA:SCHF)

Steward Partners Investment Advisory LLC Raises Holding...

Mar 10, 2025  0

Vail Resorts (NYSE:MTN) Given New $215.00 Price Target at Mizuho

Vail Resorts (NYSE:MTN) Given New $215.00 Price Target ...

Mar 12, 2025  0

Brokers Offer Predictions for Trex’s Q1 Earnings (NYSE:TREX)

Brokers Offer Predictions for Trex’s Q1 Earnings (NYSE:...

Feb 28, 2025  0